Radiation dose impacts on size of lung nodules seen on CT images
Research has shown how radiation dose can affect size of lung nodules observed on CT images.
The size of chest lymph nodes and lung nodules identified by CT images depends on the amount of radiation used for the examination.
That is according to new research from the Massachusetts General Hospital in Boston, which found lower radiation doses resulted in a more varied size of lesions seen on CT images.
The team used a 3D image processing tool to quantitatively measure the volume of lymph nodes and lung nodules.
Lymph node volumes were estimated at 30 per cent lower in five cases and ten per cent higher in 25 cases of low dose compared with higher dose images.
The study also found that the calculated volume of lung nodules was 46 per cent lower in nine cases and 34 per cent higher in ten cases on lower dose compared to higher dose images.
Lead author of the study, Dr Beth Vettiyil, said: "We think that increased image noise (graininess of the image) on the lower dose scans may have caused the lesion volumes to vary so significantly."
While the study might suggest radiologists can use these tools to supplement their measurements, Dr Vettiyil added the use of such software measurements without a clinical correlation might not be advisable yet.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...